Apar Kishor Ganti, MD

These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.